Search results

...s with EGFR mutations resistant to targetted therapies?|KRAS (primary) and T790M (primary and acquired)}}

*45% of the mutations are p.DEL19, approx 40-45% are p.L858R, approx 2% are p.T790M. *Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal | last1 = Mok | first1 = TS. | last2